Correction to: J Hematol Oncol (2020) 13:132 10.1186/s13045-020-00964-5
The original article [18] mistakenly contains duplicate references. The correct reference list can be viewed in this Correction article.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Musa Yilmaz and Mansour Alfayez have contributed equally to this work
References
- 1.Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312. doi: 10.1038/s41375-018-0357-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia. 2012;26(10):2176–2185. doi: 10.1038/leu.2012.114. [DOI] [PubMed] [Google Scholar]
- 3.Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi: 10.1056/NEJMoa1614359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061–1075. doi: 10.1016/S1470-2045(17)30416-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740. doi: 10.1056/NEJMoa1902688. [DOI] [PubMed] [Google Scholar]
- 6.Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–997. doi: 10.1016/S1470-2045(19)30150-0. [DOI] [PubMed] [Google Scholar]
- 7.Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J ClinOncol. 2013;31(29):3681–3687. doi: 10.1200/JCO.2013.48.8783. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cortes J, Perl AE, Dohner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903. doi: 10.1016/S1470-2045(18)30240-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Levis MJ, Smith CC, Ishizuka K, Kobayashi K, Arunachalam M, Wang Y, Lazzaretto D, Cortes JE. Post hoc exploratory analysis of two phase 2 trials of quizartinibmonotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. J ClinOncol. 2018;36:7017. doi: 10.1200/JCO.2018.36.15_suppl.7017. [DOI] [Google Scholar]
- 10.Perl AE. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. In: Proceedings of the 110th annual meeting of the American Association for Cancer Research; Atlanta, GA.: AACR; 2019.
- 11.Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, et al. Phase 2b study of 2 dosing regimens of quizartinibmonotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132(6):598–607. doi: 10.1182/blood-2018-01-821629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J ClinOncol. 2003;21(24):4642–4649. doi: 10.1200/JCO.2003.04.036. [DOI] [PubMed] [Google Scholar]
- 13.Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi: 10.1182/blood-2016-08-733196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–4662. doi: 10.1182/blood-2013-01-480228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Rollig C, Serve H, Huttmann A, Noppeney R, Muller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–1699. doi: 10.1016/S1470-2045(15)00362-9. [DOI] [PubMed] [Google Scholar]
- 16.NCCN Clinical Practice Guidelines in AML National Comprehensive Cancer Network 2019;Version 3.
- 17.Swaminathan M, Kantarjian H, Daver N, Borthakur G, Ohanian M, Kadia T, DiNardo C, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour E, Alvarado Y, Wierda W, Pinsoy MR, Ravandi F, Cortes J. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017;128:1642. [Google Scholar]
- 18.Yilmaz M, et al. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J HematolOncol. 2020;13:132. doi: 10.1186/s13045-020-00964-5. [DOI] [PMC free article] [PubMed] [Google Scholar]